Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

6.835 -0.855 (-11.12%)

Streaming Delayed Price Updated: 12:26 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Organon (OGN) Q4 2025 Earnings Call Transcript ↗

Today 12:33 EST

Organon (OGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook ↗

Today 8:32 EST

Via Chartmill

Topics Earnings

Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations

Today 8:01 EST

Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2...

Via StockStory

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

Today 7:30 EST

From Organon & Co.

Via Business Wire

Organon Earnings: What To Look For From OGN

February 10, 2026

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

2 Healthcare Stocks with Promising Prospects and 1 We Brush Off

February 04, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Via StockStory

Topics Stocks

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

January 29, 2026

From Organon & Co.

Via Business Wire

Organon Completes Divestiture of JADA® System to Laborie

January 28, 2026

From Organon & Co.

Via Business Wire

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Nasdaq, S&P 500 Futures Rise As Trump Diffuses Tariff Risk: Why INTC, MSFT, NFLX, RKLB, OGN Are On Traders' Radar Today ↗

January 22, 2026

Retail sentiment on Stocktwits for SPY and QQQ remains ‘bearish,’ signaling caution.

Via Stocktwits

Topics ETFs Earnings Economy

Why Are Organon (OGN) Shares Soaring Today

January 20, 2026

Shares of pharmaceutical company Organon (NYSE:OGN) jumped 8.9% in the afternoon session after reports surfaced that Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the...

Via StockStory

Topics Artificial Intelligence Initial Public Offering Supply Chain

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

January 16, 2026

From Organon & Co.

Via Business Wire

3 Small-Cap Stocks We Approach with Caution

January 07, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

3 Healthcare Stocks with Questionable Fundamentals

December 15, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...

Via StockStory

Topics Stocks

Why Organon (OGN) Shares Are Trading Lower Today

December 09, 2025

Shares of pharmaceutical company Organon (NYSE:OGN) fell 4.7% in the afternoon session after Barclays initiated coverage on the company with an 'Underweight' rating and a price target of $7.50. The new...

Via StockStory

Topics Initial Public Offering

3 Stocks Under $10 We Steer Clear Of

December 08, 2025

Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be...

Via StockStory

3 Value Stocks with Questionable Fundamentals

December 04, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

3 Cash-Producing Stocks We Find Risky

December 03, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?

November 30, 2025

Over the past six months, Organon’s stock price fell to $7.77. Shareholders have lost 16.1% of their capital, which is disappointing considering the S&P 500 has climbed by 14.7%. This may have...

Via StockStory

Topics Stocks

Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks

November 25, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From Organon & Co.

Via Business Wire

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

November 17, 2025

From Organon & Co.

Via Business Wire

The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call

November 17, 2025

Organon's third quarter was marked by better-than-expected top-line and bottom-line results, which were well received by the market. Management attributed the quarter’s outperformance to strong...

Via StockStory

Topics Earnings

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN

November 14, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Organon (OGN) Stock Trades Down, Here Is Why

November 11, 2025

Shares of pharmaceutical company Organon (NYSE:OGN) fell 2.9% in the afternoon session after the company lowered its full-year sales guidance and analysts subsequently cut their price targets on the...

Via StockStory

Topics Artificial Intelligence Initial Public Offering Supply Chain

Organon Analysts Cut Their Forecasts Following Q3 Results ↗

November 11, 2025

Via Benzinga

OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration

November 11, 2025

Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s...

Via StockStory

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗

November 10, 2025

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government...

Via Benzinga

Organon Cuts 2025 Sales Outlook Despite Earnings Beat ↗

November 10, 2025

Organon posts Q3 EPS of $1.01, topping estimates, trims 2025 sales outlook, and highlights positive Vtama data in children with atopic dermatitis.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.